X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://www.prnewswire.com/news-releases/astellas-initiates-phase-3-clinical-studies-of-fezolinetant-for-vms-associated-with-menopause-in-japan-302077555.html
https://www.prnewswire.com/news-releases/astellas-to-air-new-veozah-fezolinetant-tv-spot-during-the-super-bowl-302050011.html
https://www.prnewswire.com/news-releases/astellas-veoza-fezolinetant-approved-by-european-commission-for-treatment-of-vasomotor-symptoms-associated-with-menopause-302010530.html
https://endpts.com/pfizers-elrexfio-astellas-veozah-among-new-drugs-recommended-for-authorization-by-european-regulatory-committee/
https://www.prnewswire.com/news-releases/astellas-highlights-veozah-fezolinetant-data-at-the-2023-annual-meeting-of-the-menopause-society-301929731.html
https://pharmafile.com/news/astellas-pharma-shares-positive-results-from-phase-3b-trial-of-fezolinetant-for-menopause-symptoms/
https://www.prnewswire.com/news-releases/astellas-veozah-fezolinetant-approved-by-us-fda-for-treatment-of-vasomotor-symptoms-due-to-menopause-301823639.html
https://www.prnewswire.com/news-releases/fda-approves-novel-drug-to-treat-moderate-to-severe-hot-flashes-caused-by-menopause-301823636.html
https://www.prnewswire.com/news-releases/results-from-astellas-pivotal-phase-3-skylight-1-study-of-fezolinetant-for-vasomotor-symptoms-due-to-menopause-published-in-the-lancet-301770807.html
https://www.fiercebiotech.com/biotech/astellas-after-using-prv-has-menopause-accelerated-approval-ambition-thwarted-fda-last
https://www.prnewswire.com/news-releases/astellas-provides-update-on-fezolinetant-new-drug-application-in-us-301750449.html
https://www.prnewswire.com/news-releases/astellas-to-present-findings-from-phase-3-long-term-safety-study-of-fezolinetant-in-oral-session-at-the-north-american-menopause-society-2022-annual-meeting-301645309.html
https://www.prnewswire.com/news-releases/european-medicines-agency-accepts-astellas-marketing-authorization-application-for-fezolinetant-301637282.html
https://www.prnewswire.com/news-releases/astellas-announces-topline-results-from-phase-3-long-term-safety-study-of-fezolinetant-in-mainland-china-301617474.html
https://www.fiercebiotech.com/biotech/astellas-menopause-therapy-accepted-fda-review-6-months-after-mixed-data
https://www.prnewswire.com/news-releases/us-fda-accepts-astellas-new-drug-application-for-fezolinetant-301608116.html
https://www.prnewswire.com/news-releases/astellas-announces-topline-12-week-results-from-phase-3-study-of-fezolinetant-for-the-nonhormonal-treatment-of-vasomotor-symptoms-in-women-in-asia-301502322.html
https://www.pharmalive.com/astellas-announces-topline-results-from-long-term-phase-3-safety-study-of-fezolinetant/
https://www.prnewswire.com/news-releases/astellas-to-present-fezolinetant-12-week-findings-from-phase-3-skylight-2-trial-in-oral-session-at-the-north-american-menopause-society-2021-annual-meeting-301381589.html
https://www.prnewswire.com/news-releases/astellas-to-present-fezolinetant-12-week-findings-from-phase-3-skylight-2-trial-in-oral-session-at-the-north-american-menopause-society-2021-annual-meeting-301381589.html
https://endpts.com/astellas-scores-a-pair-of-trial-wins-for-menopausal-hot-flash-med-raising-the-pitch-of-looming-bayer-standoff/
https://www.clinicaltrialsarena.com/news/astellas-fezolinetant-vms-women/
https://www.prnewswire.com/news-releases/astellas-announces-positive-topline-results-from-two-phase-3-pivotal-global-trials-of-fezolinetant-for-the-nonhormonal-treatment-of-vasomotor-symptoms-in-postmenopausal-women-301231420.html
https://www.contractpharma.com/contents/view_breaking-news/2019-08-06/astellas-appoints-svp-and-head-clinical-and-research-qa/
https://www.prnewswire.com/news-releases/astellas-initiates-phase-3-clinical-trials-for-fezolinetant-in-postmenopausal-women-with-vasomotor-symptoms-300896688.html
Market Place
Share 
